16 Jun 2025
💊FDA Issues Regulatory Review Period for VOWST Patent Extension
Determination of Regulatory Review Period for Purposes of Patent Extension; VOWST
Summary
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOWST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$$ - High
The text details the FDA's determination of the regulatory review period for VOWST, which affects patent extensions for the product. This has direct financial implications for Seres Therapeutics, Inc., and potentially influences pricing and market strategies for other businesses in the pharmaceutical sector.